

Key ASH Presentations Issue 4, 2011

Brentuximab in Relapsed/Refractory Hodgkin Lymphoma

For more visit ResearchToPractice.com/5MJCASH2011

CME INFORMATION

OVERVIEW OF ACTIVITY

The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for hematologic cancer.

LEARNING OBJECTIVE

• Describe the mechanism of action, activity and safety of brentuximab vedotin in the setting of relapsed or refractory Hodgkin lymphoma.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Steven M Horwitz, MD Assistant Attending Lymphoma Service, Division of Hematologic Oncology Memorial Sloan-Kettering Cancer Center New York, New York

Consulting Agreements: Allos Therapeutics, Celgene Corporation, Millennium, The Takeda Oncology Company; Paid Research: Allos Therapeutics, Genzyme Corporation.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium, The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Millennium, The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Seattle Genetics.

Last review date: February 2011 Expiration date: February 2012




Click here for papers on Hodgkin lymphoma.

When one queries lymphoma investigators about the key data sets from the December ASH meeting, at the top of almost every list is a stunning **report** in which 102 patients with Hodgkin lymphoma (HL) and disease progression after a median of 3.5 prior chemotherapy treatments and an autologous stem cell transplant were treated with brentuximab vedotin. "B vedotin" is an immune conjugate, with an antibody against CD30 hooked to an antitubulin agent (monomethyl auristatin E) that is similar to vinblastine.

Like the trastuzumab/maytansine conjugate T-DM1 in breast cancer, B vedotin is thought to deliver the cytotoxic to or into the tumor cell, but the exact mechanism of antitumor effect has yet to be defined. Of great interest, unlike its breast cancer cousin, the naked antibody in B vedotin is not active in heavily pretreated HL.

In this pivotal Phase II, single-arm trial, more than 90 percent of patients had tumor responses (check out the waterfall plot), with 34 percent complete and 40 percent partial remissions. The agent was well tolerated with apparently reversible peripheral neuropathy identified as the only important toxicity. It should come as no surprise that this fascinating agent is quickly tracking through the FDA and being incorporated into ongoing and emerging clinical trials, including as consolidation after transplant and up front with ABVD.



Three other ASH presentations on HL are also profiled in our slide sets:

1. The long-awaited **Phase III ECOG/Intergroup trial** in locally extensive or bulky advanced HL randomizing between ABVD and Stanford V.

Many were disappointed to see that there was no major efficacy difference between the two arms, and in the US, ABVD remains the standard. In this trial, only patients with bulky mediastinal disease received radiation therapy with ABVD as opposed to essentially a multimodality approach with Stanford V.

2. <u>A German study</u> evaluating PET scanning in patients with advanced-stage HL and a residual mass on CAT scan greater than 2.5 cm after BEACOPP.

Ninety-two percent of patients with negative PETs were disease-free at three years without radiation therapy. Whether this can be extrapolated to ABVD is being debated.

3. <u>An Italian study</u> of interim PET scanning after two cycles of ABVD in patients with both early and advanced disease.

Patients with PET positivity did poorly and should be considered for immediate referral to a tertiary center for clinical trial consideration.

It is worth remembering that while most of the 8,000 patients diagnosed with HL annually in the US are cured, approximately 1,500 (mostly those presenting with advanced disease) are not. Fortunately, for the first time maybe ever there are a number of promising agents in development, including B vedotin, lenalidomide, panobinostat and everolimus, offering new hope that some of these mostly younger patients can be salvaged.

Next up on ASH *5-Minute Journal Club*: Another major paper on B vedotin — this time in anaplastic large cell lymphoma — and other new data in T-cell lymphomas.

Neil Love, MD **Research To Practice** Miami, Florida

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice designates each educational activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in each activity.

This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Millennium, The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Seattle Genetics.

Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131

This email was sent to you by Dr Neil Love and Research To Practice. To unsubscribe to future email requests and announcements, <u>click here</u>. To unsubscribe from all email communications, including CME/CNE activities sent by Research To Practice, <u>click here</u>. To update your information on our current distribution lists, <u>click here</u>.

Brentuximab in Relapsed/Refractory Hodgkin Lymphoma

Presentation discussed in this issue

Chen R et al. **Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma.** *Proc ASH* 2010; **Abstract 283**.

Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with Steven M Horwitz, MD (12/29/10)


Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Chen R et al. Proc ASH 2010; Abstract 283.

> Research To Practice®

For more visit ResearchToPractice.com/5MJCASH2011

Brentuximab Vedotin Mechanism of Action



Study Schema				
Accrual = 102 (Closed)				
Eligibility				
Relapsed or refractory	Brentuximab vedotin 1.8 mg/kg			
CD30+ Hodgkin	IV over 30 minutes			
lymphoma (HL) Post autologous stem	q 3 weeks x up to 16 cycles			
cell transplant (ASCT)				
Primary Objective Overall objective response rate (CR + PR) by independent review facility (IRF)				
Secondary Objectives Assess duration of response and progression-free survival (PFS) Assess overall survival Assess safety and tolerability				
Chen R et al. Proc ASH 2010;Abstract	283. Research To Practice®			

Patient Characteristics

Characteristic		
Age (median)	31 years	
Number of prior chemotherapy regimens (median)	3.5	
Primary refractory disease*	71%	
Refractory to most recent salvage therapy (excluding transplant)	42%	

* Failure to achieve a complete response or progression within 3 months of completing front-line therapy

Research To Practice[®]

Chen R et al. Proc ASH 2010; Abstract 283.


Efficacy Outcomes (n = 102)

Response	IRF	Investigator
Overall response rate (ORR)	75%	72%
Complete remission	34%	33%
Partial remission	40%	38%

Secondary endpoints	IRF	Investigator
Progression-free survival	25.1 weeks	39.1 weeks
Median duration of ORR	29 weeks	47 weeks
Median duration of CR	Not reached	Not reached
Overall survival (OS)	Not reached	Not reached
Estimated 12-month OS	88%	

Chen R et al. Proc ASH 2010; Abstract 283.

Maximum Tumor Reduction per IRF



Select Safety Events

Treatment-Related Adverse Events (AE) Peripheral sensory neuropathy	All Grades* 47%	Grade 3 or 4* 8% [†]
Fatigue	46%	Not reported
Nausea	42%	Not reported
Diarrhea	36%	Not reported
Neutropenia	22%	20%

* All Grade AEs occurring in ≥20% of patients and Grade 3/4 AEs occurring in ≥5% of patients

⁺ Grade 3 only

Chen R et al. Proc ASH 2010; Abstract 283.

Author Conclusions

- Brentuximab vedotin is associated with encouraging activity in patients with heavily pretreated, relapsed/refractory HL.
 - ORR = 75% (median duration of response of 29 weeks by IRF)
 - CR = 34% (median duration not reached)
 - Patients achieving tumor reduction = 94%
 - Estimated 12-month OS = 88%
- Brentuximab vedotin treatment is associated with a manageable adverse-events profile.
 - Peripheral neuropathy largely reversible
- Brentuximab vedotin enables selective delivery of a potent cytotoxic agent to patients with relapsed/refractory HL.
- Ongoing Phase III AETHERA Trial is comparing brentuximab vedotin versus placebo in patients with residual Hodgkin lymphoma after ASCT (NCT01100502).

Research

Chen R et al. Proc ASH 2010; Abstract 283; www.clinicaltrials.gov, January 2011To Practice®

Investigator comment on brentuximab for patients with relapsed/refractory Hodgkin lymphoma

I believe in terms of the new drugs, brentuximab caused the most excitement at ASH because these are high response rates in a study that was well done. These data are compelling, and I believe there is a good chance that the drug will be approved for relapsed/refractory Hodgkin lymphoma. I also think there will be an expanded access or compassionate use program while approval is pending.

There is also interest in moving this drug into earlier lines or even up front for poor-risk Hodgkin lymphoma. The main issue with combining it with the current up-front regimens is neuropathy, as vinca alkaloids, which are universally used up front, are also neuropathic. Hematologic toxicity, I believe, is less likely to be a problem. There could be many ways to potentially add this drug and help people with Hodgkin lymphoma.

Interview with Steven M Horwitz, MD, December 29, 2010